News ABIONYX Pharma Börse Stuttgart

Equities

609 FR0012616852

Market Closed - Börse Stuttgart Other stock markets 07:04:07 17/05/2024 pm IST			5-day change	1st Jan Change
1.032 ^EUR	-5.84%		+10.15%	-42.73%

14/03	Abionyx Pharma: to benefit from a 1ME grant from Bpifrance	CF
11/03	Abionyx: reduced net loss in 2023	CF

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ABIONYX Pharma Provides an Update on Its Activity and Cash Position for the 1st Quarter 2024	16/05	BU
ABIONYX Pharma: Availability of the Universal Registration Document for the Year 2023	02/05	BU
Abionyx Pharma: to benefit from a 1ME grant from Bpifrance	14/03	CF
ABIONYX Pharma - Bpifrance Supports the Development of CER-001 in Ophthalmology With a Nearly €1 Million Non-dilutive Innovation Grant	14/03	BU
Abionyx: reduced net loss in 2023	11/03	CF
ABIONYX Pharma Announces Its 2023 Full-Year Financial Results	11/03	BU
ABIONYX Pharma SA Reports Earnings Results for the Full Year Ended December 31, 2023	11/03	CI
ABIONYX Pharma announces its financial calendar for the year 2024	08/03	BU
Abionyx: CSL Behring fails in heart disease trial	16/02	CF
ABIONYX Pharma SA Acknowledges the Clinical Results of the Phase 3 Aegis-Ii Study Evaluating the Efficacy and Safety of Csl Behring?S Human-Plasma-Derived Apoa-I, CSL112	15/02	CI
Abionyx: former AbbVie executive appointed CMO	09/01	CF
ABIONYX Pharma Appoints Rob Scott as Chief Medical Officer and Head of R&D	08/01	CI
Abionyx: Successful completion of third GMP batch of CER-001	19/12	CF
2,867,986 Ordinary Shares of ABIONYX Pharma SA are subject to a Lock-Up Agreement Ending on 7-DEC-2023.	07/12	CI
Abionyx: encouraging results in brain fog	24/11	CF
ABIONYX Pharma : Inside Information / Other news releases	24/11	PU
ABIONYX Pharma Presents Preclinical Results for CER-001 in Brain Fog, At the 1st International Scientific Congress on Brain-Kidney Interaction in Naples on November 23-24, 2023	24/11	CI
Abionyx: promising new results in uveitis	21/11	CF
ABIONYX Pharma Announces New Positive Results in a Uveitis Model for the Strategic Development of the First Class of Biomedicines in Ophthalmology Based on its Recombinant apoA-I	21/11	CI
Abionyx: cash position reaches 1.7 million euros	17/11	CF

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News ABIONYX Pharma Börse Stuttgart

Equities

609

FR0012616852

Summary

Filters